Souhaitez-vous accéder aux communiqués récents ?

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE)...

BALTIMORE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month and to help people keep life flowing smoothly, the Urology Care Foundation (UCF), the official foundation of...

Patent for composition of matter and methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 and combination use with therapeutic pair ⁶⁷Cu-NU101

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance 36% to 38% Annual YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal...

Koelis announces final ruling of designated CPT I codes for fusion biopsy and transperineal biopsy in prostate cancer diagnosis.

PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine,...

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and...

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of EpCAM-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...